
    
      This is a prospective, multi-center, randomized, controlled, observer-blind, Phase 1 trial in
      healthy male and female adults 18 through 39 years of age to evaluate safety and the immune
      response of a prime boost regimen with LAIV prime and IIV boost with or without adjuvant.
      Participants will be randomized 4:3:1:3:2 to one of five groups to receive a first dose of
      study cH8/1N1 LAIV (or placebo) or study cH8/1N1 IIV + AS03A adjuvant (or placebo) followed
      three months later by study cH5/1N1 IIV +/- AS03A adjuvant (or placebo).
    
  